Vaccines-2013 - OMICS Group

Recommendations

Info

I. Khalili et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAChitosan as an adjuvant for preparation of inactivated influenza vaccineI. Khalili 1 , M. Fathi Najafi 1 and S. Avagyan 21Razi Vaccine & Serum Research Inst.Northwest, Iran2Agrarian National University Armenia ANUA Yerevan, ArmeniaInfluenza A viruses infects a wide range of animal species and human. Among the avian influenza virus (AIV) subtypes,H9N2 would be used for rapid intervention should be safe to use and highly effective after a single administration. Chitosanmicroparticles have already been proposed as a new adjuvant in inactivated avian Influenza (H9N2) vaccine immunization. Virushas the potential to cause an influenza pandemy and vaccination is a common solution for this problem. The aim of the presentwork was to investigate the potential utility of chitosan microparticles as new parenterally vaccine delivery vehicles.For this purpose, chitosan microparticles were prepared according to a modified ionic gelation method and inactivatedantigen was loaded in 1 HAU concentration. Loading capacity of microparticles was determined by Hemaglutinization (HA)method. ISA70 vaccine as a standard adjuvant with same loading size was used in beside. For vaccine-antibody response assay,different volumes of prepared vaccines (0.2, 0.4 and 0.6 ml) were injected via subcutaneous rout in 21-days-old specific pathogenfree cheekiness. Vaccine induced AIV-specific antibodies after single vaccination, measured at 6 weeks after vaccination withHemagglutinin Inhibition (HI) and ELISA methods.Elisa and HI Log 2 total mean titer of chitosan groups were significantly increased in 3 weeks after vaccine administration(p0.05). Titer of ISA70experimental vaccine in mentioned preparations condition was not reasonable.So, these kinds of vaccines induce appropriate antibody titers after a single immunization and with a low dose of antigen.Also, chitosan microparticles represent an interesting new platform for antigen delivery and a promising adjuvant candidate forH9N2 inactivated influenza vaccine.Keywords: Chitosan, microparticle, adjuvant, influenza, virus, ELISABiographyIraj Khalili is Director Manager at Razi vaccine and serum research institute. He graduated at DVM in 1995. He started his job at Razi Companyin 1997 in fi eld of pharmaceutical and vaccine producing. There are more than 60 biological productions in fi eld of veterinary and medicine. He isincharge of Razi vaccine and serum research institute (Northwest) branch since 2007. He is planning his Ph.D. pre-defence at ANUA in Armenia.iraj_dv4953@yahoo.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 120
Hemanta Koley et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAImmunogenicity and protective efficacy of multi-serotype outer membrane vesicles ofshigellae in animal modelHemanta Koley and Soma MitraNational Institute of Cholera and Enteric Diseases, IndiaImmunization of adult female mice with outer membrane vesicles (OMVs) of Shigella boydii type 4 protected their offspringpassively from shigellosis. Now, we have advanced our research by formulating multi-serotype outer membrane vesicles(MOMVs) mixing the OMVs of S. dysenteriae 1 Δstx, S. flexneri 2a, S. flexneri 3a, S. flexneri 6, S. boydii type 4 and S. sonnei toachieve a broad spectrum protection against shigellosis. Adult mice were immunized orally with 50μg of MOMVs, four timesat weekly intervals. Immunological parameters were observed at various time points, before, during and after immunization,in adult mice. Passive protection was examined in their offspring by measuring protective efficacy and studying intestinalcolonization, after challenging with various Shigella strains. Immunized dams exhibited a consistent broad spectrum antibodyresponse. Three to four day-old offspring of immunized dams showed significant long term passive protection against Shigellaflexneri 2a, 3a, 6, S. boydii type 2 and S. dysenteriae 1 challenge. Their stomach extracts, containing mainly milk from the dams,have also exhibited significant levels of anti-MOMVs immunoglobulins. In conclusion, MOMVs formulation represents an easy,safe immunization strategy that was found suitable to provide complete passive protection to the neonatal mice against all fourserogroups of Shigellae. This formulation could be exploited for the development of a novel non-living vaccine against humanshigellosis in our near future.BiographyHemanta Koley, after completion of his master’s degree in Human Physiology from Calcutta University, he joined in NICED, Beliaghata, Calcutta,India, for his Ph.D. work. In 1996, he worked as Associate Professor in College of Medical Sciences, Nepal, where he devoted entire heartily inteaching medical students till 2001. He moved to Rutgers-The State University of New Jersey, New Brunswick, USA for postdoctoral research. Healso worked in Gastroenterology Section, Harvard Medical School as Research Associate. His present research interest is to understand signaltransduction pathways in immune and infl ammatory cells during diarrhoea and also to study the nature of protection against diarrhoeal pathogenslike Vibrio cholera, Salmonella and Shigella in different animal models. He has published 43 original papers and 50 abstracts in his credit. He hassecured patent for a process for the preparation of Cholera Vaccine-VA1.3. (European Patent Offi ce; Patent No. - 97309957.5-2105 on 19/05/98).Dr. Koley received Young Scientist Award in IUPS, August 26-31, 2001.hemantakoley@hotmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 121
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62:
Track 44: Vaccines against Infectio
Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119: Afshineh Latifynia et al., J Vaccin
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
Page 157 and 158: Veronica Rainone et al., J Vaccines
Page 159 and 160: Page 159
Page 161 and 162: Previous111 th OMICS Group Conferen
Page 163 and 164: PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?